Association of Pneumococcal Conjugate Vaccine Coverage With Pneumococcal Meningitis: An Analysis of French Administrative Areas, 2001-2016

Overview

Journal Am J Epidemiol

Publisher Oxford University Press

Specialty Public Health

Date 2019 Jun 15

PMID 31197305

Citations 1

Authors

Anna Alari

Felix Cheysson

Lenaig Le Fouler

Philippe Lanotte

Emmanuelle Varon

Lulla Opatowski

Didier Guillemot

Laurence Watier

Affiliations

Soon will be listed here.

Abstract

Geographic variations of invasive pneumococcal disease incidence and serotype distributions were observed after pneumococcal conjugate vaccine introduction at regional levels and among French administrative areas. The variations could be related to regional vaccine coverage (VC) variations that might have direct consequences for vaccination-policy impact on invasive pneumococcal disease, particularly pneumococcal meningitis (PM) incidence. We assessed vaccine impact from 2001 to 2016 in France by estimating the contribution of regional VC differences to variations of annual local PM incidence. Using a mixed-effect Poisson model, we showed that, despite some variations of VC among administrative areas, vaccine impact on vaccine-serotype PM was homogeneously confirmed among administrative areas. Compared with the prevaccine era, the cumulative VC impact on vaccine serotypes led, in 2016, to PM reductions ranging among regions from 87% (25th percentile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes. Nonvaccine-serotype PM increases from the prevaccine era ranged among areas from 98% to 127%. By taking into account the cumulative impact of growing VC and VC differences, our analyses confirmed high vaccine impact on vaccine-serotype PM case rates and suggest that VC variations cannot explain PM administrative area differences.

Citing Articles

How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.

Bjar N, Hermansson A, Gisselsson-Solen M Infection. 2024; 52(4):1377-1384.

PMID: 38416397 PMC: 11289216. DOI: 10.1007/s15010-024-02195-z.

References

Weisfelt M, de Gans J, van der Ende A, van de Beek D . Community-acquired bacterial meningitis in alcoholic patients. PLoS One. 2010; 5(2):e9102. PMC: 2817003. DOI: 10.1371/journal.pone.0009102. View

Takala A, Jero J, Kela E, Ronnberg P, Koskenniemi E, Eskola J . Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA. 1995; 273(11):859-64. View

Opatowski L, Varon E, Dupont C, Temime L, van der Werf S, Gutmann L . Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from statistical and mathematical models. Proc Biol Sci. 2013; 280(1764):20130519. PMC: 3712413. DOI: 10.1098/rspb.2013.0519. View

Ihekweazu C, Dance D, Pebody R, George R, Smith M, Waight P . Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect. 2007; 136(8):1096-102. PMC: 2870895. DOI: 10.1017/S0950268807009715. View

Schonheyder H, Sorensen H, Kristensen B, Korsager B . Reasons for increase in pneumococcal bacteraemia. Lancet. 1997; 349(9064):1554. DOI: 10.1016/s0140-6736(05)62135-6. View

Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D . Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008; 13(35). DOI: 10.2807/ese.13.35.18962-en. View

Lundbo L, Benfield T . Risk factors for community-acquired bacterial meningitis. Infect Dis (Lond). 2017; 49(6):433-444. DOI: 10.1080/23744235.2017.1285046. View

Murdoch D, Jennings L . Association of respiratory virus activity and environmental factors with the incidence of invasive pneumococcal disease. J Infect. 2008; 58(1):37-46. DOI: 10.1016/j.jinf.2008.10.011. View

Levine O, Farley M, Harrison L, LEFKOWITZ L, McGeer A, Schwartz B . Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999; 103(3):E28. DOI: 10.1542/peds.103.3.e28. View

10.

Hausdorff W, Siber G, Paradiso P . Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001; 357(9260):950-2. DOI: 10.1016/S0140-6736(00)04222-7. View

11.

Rosen J, Thomas A, Lexau C, Reingold A, Hadler J, Harrison L . Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011; 53(2):137-43. DOI: 10.1093/cid/cir326. View

12.

Cartwright K . Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr. 2002; 161(4):188-95. DOI: 10.1007/s00431-001-0907-3. View

13.

McCullers J, McAuley J, Browall S, Iverson A, Boyd K, Henriques Normark B . Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis. 2010; 202(8):1287-95. PMC: 3249639. DOI: 10.1086/656333. View

14.

Hausdorff W, Black S . What is the heterogeneity in the impact seen with pneumococcal conjugate vaccines telling us?. Vaccine. 2017; 35(31):3797-3800. DOI: 10.1016/j.vaccine.2017.05.089. View

15.

Hausdorff W . Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr. 2002; 161 Suppl 2:S135-9. DOI: 10.1007/s00431-002-1066-x. View

16.

Austin P, Stryhn H, Leckie G, Merlo J . Measures of clustering and heterogeneity in multilevel Poisson regression analyses of rates/count data. Stat Med. 2017; 37(4):572-589. PMC: 5813204. DOI: 10.1002/sim.7532. View

17.

Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L . Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017; 65 Suppl 4:S149-S167. DOI: 10.1016/j.respe.2017.05.004. View

18.

Alari A, Chaussade H, Domenech de Celles M, Le Fouler L, Varon E, Opatowski L . Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Med. 2016; 14(1):211. PMC: 5175381. DOI: 10.1186/s12916-016-0755-7. View

19.

Jusot J, Neill D, Waters E, Bangert M, Collins M, Moreno L . Airborne dust and high temperatures are risk factors for invasive bacterial disease. J Allergy Clin Immunol. 2016; 139(3):977-986.e2. PMC: 5338876. DOI: 10.1016/j.jaci.2016.04.062. View

20.

Jefferson T, Ferroni E, Curtale F, Rossi P, Borgia P . Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis. 2006; 6(7):405-10. DOI: 10.1016/S1473-3099(06)70520-5. View